AbbVie Inc. closed $6.48 below its 52-week high ($199.95), which the company reached on September 3rd.

The stock's fall snapped a two-day winning streak.

AbbVie Inc.’s TV advertisements featuring tennis legend Serena Williams make misleading claims about the effectiveness of its ...

If you want to know who really controls AbbVie Inc. ( NYSE:ABBV ), then you'll have to look at the makeup of its share ...

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with ...

We recently published a list of 10 Best Big-Name Stocks to Buy Right Now According to Short Sellers. In this article, we are ...

AbbVie Inc (ABBV) stock saw a modest uptick, ending the day at $196.42 which represents a slight increase of $3.02 or 1.56% from the prior close of $193.4. The stock opened at $194.97 and touched a ...

DCF analysis, a reliable and data-driven approach to estimating its intrinsic value. Instead of using future free cash flow ...

But the risk of a serious side effect appears to be higher than previously known. By Anna Kodé AbbVie for years delayed competition for its blockbuster drug Humira, at the expense of patients and ...

AbbVie Inc (Symbol: ABBV) has been named to the Dividend Channel ''S.A.F.E. 25'' list, signifying a stock with above-average ''DividendRank'' statistics including a strong 3.2% yield, as well as a ...